The Weekly Checkup: Week of June 8-12, 2026

Issue #10 | Week of June 8-12, 2026

56 announced transactions this week, up from last week's 46, with Services 28, Technology 28, and 5 platform deals. The volume is back up and the deal quality is strong to quite strong.

Deal value: $900M for 40% | 100% implied EV: ~$4.7 billion | EV / Revenue: 2.29x

Humana agreed to sell substantially all of its 40% minority stake in Gentiva, the nation's largest hospice provider by Medicare claims, to a consortium of investors for $900 million. The 40% stake implies a 100% enterprise value of approximately $4.7 billion, as the company currently carries approximately $2.46 billion in debt per S&P Global research. Per Humana’s latest 10-k, Gentiva generated FY2025 revenue of approximately $2.05 billion.

My take: The 2.29x revenue multiple is toward the high end of the range for hospice, but not at the high end, and reflects both Gentiva's market position and the structural tailwinds in hospice: aging demographics, terminal prognosis, Medicare fee-for-service reimbursement that is broadly stable, and a regulatory framework that creates high barriers to entry in established markets.

The S&P report is worth pausing on, because it discloses something that meaningfully changes the implied EBITDA multiple. S&P uses "EBITDA at default" as a metric in its recovery analysis, which is a standardized estimate of the EBITDA level at which a company would be expected to default on its obligations, typically calculated as the annual debt service requirement divided by an assumed coverage ratio. It is not the same as operating EBITDA; it is a conservative floor figure used to model recovery rates in a distressed scenario. S&P's disclosed EBITDA at default for Gentiva is approximately $313 million, which means Gentiva's actual operating EBITDA is likely materially above that figure, which also means the implied EV/EBITDA multiple was likely less than the 15x the at-default figure that the EV implies. If Gentiva's operating EBITDA is running at, say, $350 to $400 million (completely made up numbers, do not use them), then the implied EV/EBITDA on actual performance is closer to 12x to 13x.

Deal value: $1.2 billion upfront + $250M milestone | EV / Revenue: 8.0x | EV / EBITDA: 19.0x

Novanta announced the acquisition of Riverpoint Medical, a Portland, Oregon-based developer and manufacturer of private-label minimally invasive surgical consumables and instruments, from Arlington Capital Partners. Riverpoint generates approximately $150 million in revenue with adjusted gross margins above 50% and adjusted EBITDA margins of approximately 40%, implying roughly $63 million in EBITDA. Organic growth is running 12% to 15% annually.

My take: The 19x EBITDA multiple at the upfront price, disclosed explicitly in the press release, is the number to dwell on. It’s not cheap, but it may not be irrational for a business with these specific characteristics. Riverpoint's 40% EBITDA margin on $150 million in revenue and 12% to 15% organic growth puts it in the top tier of medtech manufacturing assets in terms of financial quality. The private-label OEM model, where Riverpoint designs and manufactures IP-protected consumables for branded medical device companies who then market them, creates deep customer stickiness: Riverpoint manages the 510(k) clearance process for its OEM customers, which means switching away from Riverpoint requires restarting a regulatory process that could take two to three years. That switching cost, plus the proprietary coating and material science IP across sports medicine, trauma, and cardiovascular consumables, is why the multiple is pushing nosebleed territory for this type of business. Arlington Capital held Riverpoint for seven years before this exit. For anyone advising PE-backed medtech manufacturers with defensible IP and OEM customer concentration, this transaction is probably a ceiling multiple for the category right now.

Deal value: $900 million | EV / Revenue: 2.42x | EV / Operating Income: 29.1x

Mitsui Chemicals America announced the acquisition of Ultradent Products, a South Jordan, Utah-based developer and manufacturer of dental materials and devices, for $900 million. Ultradent reported FY2025 revenue of $372.1 million and operating income of $30.9 million, an 8.3% operating margin. Mitsui plans to transfer its global oral care business headquarters to the US and pursue synergies with its Kulzer dental brand through combined R&D and cross-selling. Earlier this week, Ultradent completed the acquisition of Azena Medical, a dental soft-tissue diode laser manufacturer, which is presumably included in the $900 million enterprise value, and pro forma adjustments have probably not been made in the financial results.

My take: The 29.1x operating income multiple looks punishing until you remember that operating income and EBITDA are not the same number, and dental materials businesses with significant manufacturing and R&D infrastructure typically carry enough depreciation and amortization to make the EBITDA multiple materially more reasonable than the operating income multiple implies. Ultradent's 8.3% operating margin on $372 million in revenue is at the low end for a branded dental materials company with proprietary chemistry and global distribution, which suggests either significant ongoing R&D investment flowing through the P&L, a manufacturing cost structure that has not been fully optimized, or both. The 2.42x revenue multiple is the more useful reference for comparable transactions: branded dental products companies with international distribution and defensible IP have been trading in the 2x to 4x revenue range in recent years, and 2.42x on a business of this scale is toward the conservative end of that range. Mitsui is not paying for current earnings; it is paying for the Ultradent brand, the global distribution infrastructure, and the strategic option value of combining Ultradent's direct-to-dentist channel with Kulzer's laboratory and indirect business. The Azena acquisition, announced days before the Mitsui deal, adds laser device capability to an otherwise chemistry-and-materials portfolio and suggests Ultradent was actively expanding its product footprint immediately before the sale.

Matt Holt's Thoreau Group, backed by Apollo Global Management, is reportedly in advanced discussions to acquire Ensemble Health Partners from Warburg Pincus, Berkshire Partners, and Bon Secours Mercy Health in a transaction valued at approximately $12 billion. Ensemble is a Blue Ash, Ohio-based end-to-end RCM company serving mid-sized to large health systems, managing revenue cycle operations from patient intake through revenue collection across hundreds of hospital clients. Per Octus, Ensemble generates EBITDA in the low-$700 million range, implying a transaction multiple of approximately 17x EBITDA at the $12 billion enterprise value.

My take: The Ensemble transaction is one of the more analytically interesting deals in this newsletter's history, because Scope Research has financial data on every prior ownership change in the company going back to its origin. The progression is worth laying out.

In 2016, Mercy Health (now Bon Secours Mercy Health) acquired the remaining controlling interest in Ensemble (then called Executive Revenue Cycle Partners) for approximately $60 million plus contingent consideration with a fair value of $46 million, implying a total enterprise value of approximately $106 million. The audited financial statements showed FY2016 revenue of $48 million and EBITDA of $13 million, a 27.1% margin. The implied multiple was 8.2x EBITDA.

In 2019, Golden Gate Capital acquired a 52% majority interest from Bon Secours Mercy Health for $1.2 billion, implying a total enterprise value of $2.31 billion. Audited financial statements showed FY2019 revenue of $592 million and EBITDA of $153 million, a 25.8% EBITDA margin. The implied multiple was 15.1x EBITDA. Revenue had grown approximately 12x in three years. EBITDA had grown approximately 12x as well.

In 2022, Warburg Pincus and Berkshire Partners acquired the company in a transaction valuing it north of $5 billion, according to press reporting. At the time, Ensemble was generating approximately $300 million in EBITDA annually, implying a multiple of approximately 16.7x EBITDA.

Today, if the Octus-reported EBITDA in the low-$700 million range is accurate and the deal closes at $12 billion, the implied multiple is approximately 17x EBITDA. Four transactions, spanning ten years and four ownership groups, the last three all clearing in a band of 15x to 17x EBITDA despite a more than 50x increase in the underlying EBITDA. The multiple stability across a decade of extraordinary growth is itself an analytical observation: quality assets in the RCM category command a consistent institutional premium that reflects the mission-critical, high-switching-cost, long-contract nature of the end-to-end outsourcing model.

The buyer profile is the other notable element. Thoreau Group is a relatively new investment platform led by Matt Holt, a former New Mountain Capital executive, and backed by Apollo. A $12 billion acquisition is an unusually large debut transaction for a young platform, and the Apollo backing suggests the financing structure will likely include a significant private credit component alongside traditional leverage. JPMorgan reportedly ran the auction; Goldman Sachs was advising on the parallel IPO track that appears to have been set aside in favor of a direct sale. For anyone in the RCM space trying to understand where the category trades at scale: the Ensemble progression from $106 million enterprise value in 2016 to $12 billion in 2026 on $700 million of EBITDA is the most complete dataset available for any single end-to-end RCM platform.

GSK announced the acquisition of Nuvalent, a Boston-based clinical-stage biopharmaceutical company, for $124 per share in cash, a 40% premium to the prior close. Nuvalent's pipeline includes zidesamtinib, a next-generation ROS1 inhibitor with a PDUFA date of September 18, 2026, and neladalkib, a next-generation ALK inhibitor with a PDUFA date of November 27, 2026, both for non-small cell lung cancer. Both have FDA Breakthrough Therapy and Orphan Drug designations. A third early-stage HER2-altered NSCLC program is also included.

My take: GSK is buying a pipeline to bridge a revenue gap: dolutegravir, its best-selling HIV drug, loses exclusivity beginning in 2028, and analysts project the combination of zidesamtinib and neladalkib could generate roughly $800 million to $900 million in annual revenue by 2029. At $10.6 billion for that peak revenue projection plus the HER2 program and the platform option value, GSK is paying a meaningful premium and accepting both regulatory and commercial risk. The deal is guided as dilutive to core EPS through 2028, accretive in 2029. The 40% premium and $10.6 billion price reflect a competitive process and GSK's urgency. Whether the two assets collectively justify that price depends almost entirely on the FDA decisions in September and November.

HCA Healthcare agreed to acquire the Medical Technology Management Institute, a medical imaging training and continuing education provider. This is HCA's second acquisition in the workforce and training space this month, following its acquisition of The College of Health Care Professions in Issue #8.

My take: Two workforce-pipeline acquisitions in the same month from the same buyer is not a coincidence. HCA is building a vertically integrated talent supply chain: CHCP trains allied health workers at scale across ten Texas campuses, and MTMI trains medical imaging technologists and provides continuing education for existing staff. The imaging technologist shortage is a specific and acute labor market problem: MRI and CT technologist vacancy rates at large health systems are running in the double digits, and imaging capacity is increasingly limited by staff availability rather than equipment availability. For HCA, owning a training institution that produces imaging technologists and provides their continuing education creates first-look hiring access to a constrained talent pool. The regulatory complexity of operating two accredited educational institutions as subsidiaries of a for-profit hospital system is substantial, but HCA is clearly prepared to accept it. Competitors who have not made similar moves are probably watching closely and may be in the market for similar assets.

StrideCare, a physician-led network focused on comprehensive lower extremity care, announced a partnership with Vascular Surgery Associates, a 35-year-old Baltimore-area vascular practice with 11 clinical locations, nine vascular surgeons, a podiatrist, an integrated wound care center, ambulatory surgery centers, and in-house vascular labs. Two of the active listings we’re taking a look at this week are highly relevant to this one.

My take: StrideCare is one of the more interesting platform concepts in the physician practice consolidation space, and this acquisition is worth understanding in the context of the Illinois vascular clinic in this week's listings. StrideCare's model is built on a clinical insight that has not yet been fully arbitraged by the market: the lower extremity patient is frequently the same patient regardless of whether they present to a podiatrist, a vascular surgeon, or a wound care clinic. A diabetic patient with peripheral arterial disease and a foot wound needs all three. Historically, those three specialties operate in separate silos, bill independently, and refer to each other episodically. StrideCare is assembling them under a single clinical and management infrastructure, which creates several compounding advantages: higher per-patient revenue capture, better clinical outcomes from coordinated care, and a more defensible payer contracting position because the platform can accept risk for the entire lower extremity care episode rather than just a piece of it.

Vascular Surgery Associates is a particularly strategic acquisition within that thesis. The 35-year operating history in the Baltimore market means deep referral relationships with orthopedic surgeons, primary care physicians, nephrologists, and endocrinologists — all of whom manage patients who eventually need vascular intervention. The integrated ASC and vascular lab infrastructure is what makes the acquisition economically compelling beyond the physician relationships alone: when a platform owns both the diagnostic capability (the vascular lab) and the procedural setting (the ASC), the revenue capture on a single patient episode is substantially higher than when the vascular surgeon performs the diagnostic study in one location and the procedure in another facility they do not own. In-office vascular procedures have recently received OIG scrutiny, but ASCs have been largely absent from those concerns so far.

The podiatry connection runs deeper than it looks in the press release. Podiatry has been consolidating steadily, as we covered in Issue #1 with Upperline Health and UW Health, for exactly the same reason StrideCare is building a lower extremity platform. Peripheral arterial disease is present in approximately 20% to 30% of diabetic patients, and undiagnosed or undertreated PAD is the primary driver of diabetic foot ulcers progressing to amputation. Podiatrists who operate independently cannot identify or treat the vascular component of a patient's lower extremity disease. Vascular surgeons who operate independently often see patients too late, after the wound has already progressed. A coordinated care model that puts a podiatrist and a vascular surgeon in the same network, sharing clinical data and co-managing the diabetic foot patient, produces meaningfully better outcomes and meaningfully higher revenue per patient than either specialty produces operating alone. StrideCare's partnership with Vascular Surgery Associates, which already includes a podiatrist on staff, is precisely the integrated model that value-based care payers are trying to incentivize and that the fee-for-service reimbursement system has historically failed to reward.

I tracked 50 additional transactions this week, including the merger of Ascension Emergency Physicians and PEPA into Franciscan Emergency Physicians in Louisiana; Med-Metrix's acquisition of CanAide (Medicaid eligibility and enrollment, a natural extension of the Vitalware integration); HST Pathways receiving a growth investment from Novo Holdings alongside existing backers Bain Capital and Nexxus Holdings; Johnson & Johnson's acquisition of Firefly Bio for $1 billion in cash to access its degrader antibody conjugate platform for KRAS-driven tumors; Dexcom's acquisition of Nutrisense (continuous glucose monitoring consumer platform); Advantage Behavioral Health's planned acquisition by QCF/I through up to $653.4 million in NJEDA conduit bond financing; and several notable home-based services transactions including Chambers Home Health & Hospice's partnership with Lucent Health Group in Northeast Texas. The complete list is available to subscribers.

A Vault deal each week pulls something from the Scope database and walks through what the underlying documents actually said.

This week: the acquisition of Orchard Park Hospital, a 30-bed inpatient pediatric psychiatric hospital in Wheeling, West Virginia, by WVU Medicine Wheeling Hospital. The deal was announced in February 2026, and is currently going through the regulatory review process.

Deal value: $19.5 million | EV / Revenue: 3.47x | EV / EBITDA: Not meaningful (operating at a loss)

What the press release said: Two nonprofit organizations announced a merger, Orchard Park Hospital, a subsidiary of The Children's Home of Wheeling, and WVU Medicine Wheeling Hospital. The announcement described the combination as expanding access to pediatric psychiatric care through the resources of a much larger health system and framed the deal in mission rather than financial terms. No purchase price was mentioned in the press release.

What the CON filings added: West Virginia's certificate of need process produced a more granular picture, showing a stated acquisition price of $19.5 million. Critically, however, Orchard Park was carrying $13 million of long-term debt that WVU Health is assuming as part of the transaction, meaning the purchase is primarily a debt and other liability assumption rather than a cash payment, although there is a cash component for the “value of assets, etc.”

The hospital opened only in 2023, just three years ago, and the CON financial projections show estimated 2027 revenue of approximately $5.6 million against a loss of approximately $171,000, making any EBITDA multiple irrelevant. A 3.5x revenue multiple appears quite high for an asset that isn’t projected to be particularly profitable even a few years out.

Why the price doesn't tell you much here: This is a nonprofit-to-nonprofit transaction, and in that context the stated "price" may just be an accounting construct. WVU Health is not writing a check to the selling shareholder, as there is no selling shareholder. It is absorbing Orchard Park's debt and operational obligations and is likely making a small payment to a foundation with a similar charitable mission to its own, in exchange for control of the hospital's license, its beds, its staff, and its physical plant.

Why WVU Health wants it: The Orchard Park acquisition makes strategic sense for WVU Health on several levels that the financial projections do not capture. First, West Virginia has the most severe psychiatrist shortage of any state in the country — only 5.7% of the adequate supply of psychiatrists needed to serve the population, according to the 2026 Trilliant Health Behavioral Health Report — and the state's pediatric inpatient psychiatric capacity has been actively contracting. In early 2026, River Park Hospital closed its 22-bed Barboursville School facility for children in Cabell County, reducing the statewide supply of pediatric inpatient beds further. West Virginia has been sending hundreds of children in foster care to out-of-state facilities due to the in-state shortage. Orchard Park's 30 beds, split across a 13-bed child unit, 13-bed adolescent unit, and four-bed special care unit, are among the only pediatric inpatient psychiatric beds in the northern panhandle.

Second, Orchard Park is located across the street from WVU Medicine's planned $122.6 million outpatient cancer center, which is scheduled to open in October 2028. WVU Health CEO Albert Wright explicitly told Becker's that the Orchard Park acquisition "will begin to create a larger downtown Wheeling campus." The acquisition is a real estate and campus development play as much as a clinical one.

Third, and most relevant to the financial picture: Orchard Park's current operating loss almost certainly reflects underutilization rather than structural unviability. A 30-bed inpatient psychiatric hospital opened in 2023 needs time to build its referral network and census to reach breakeven. Pediatric inpatient psychiatric hospitals are highly sensitive to occupancy: at low census, the fixed cost of 24-hour nursing, psychiatry coverage, and facility operations creates significant losses; at full or near-full census, the same cost structure generates meaningful operating margins. The revenue projection of $5.6 million at estimated 2027 census implies an average daily census well below the 30-bed capacity. WVU Health, with its existing physician relationships at Wheeling Hospital, its connections to the WVU Medicine Golisano Children's program, and its network of referring emergency departments across the region, is positioned to accelerate census in ways that an independent 30-bed hospital cannot.

Fourth, the reimbursement environment for inpatient pediatric psychiatric care in West Virginia is improving at the margin. West Virginia Medicaid reimbursement rates for behavioral health services have been described by the WV Behavioral Healthcare Providers Association as "stagnant for years," but there has been bipartisan legislative pressure to address the gap, particularly for pediatric services, given the high-profile cases of foster children being placed out of state. Any meaningful Medicaid rate improvement flows directly to operating margin in a high-fixed-cost inpatient psychiatric setting.

Scope Research's valuation database has approximately 2,900+ healthcare M&A transactions with disclosed or derived revenue and EBITDA multiples going back to 2010. CON filings are among the most reliable sources of granular financial data for healthcare transactions in regulated states, and we build our database entries on those documents wherever they exist.

Location: Illinois (near Indiana border) | Asking Price: $3.9M | Revenue: $3.47M | Cash Flow: $840K | CF Margin: 24.2% | Price / Revenue: 1.12x | Price / Cash Flow: 4.64x

Established in 2022 as an offshoot of a 15-year-old PE-backed chain of medical centers. Specialized vascular clinic focused on niche procedures with significant growth. Exact procedures undisclosed.

My take: A vascular clinic generating $3.47 million in revenue in four years from a standing start is growing quickly, and is either building the referral network that makes it a logical acquisition candidate for a lower extremity care platform like StrideCare, or it has not yet built that network and the revenue is more fragile than the growth rate implies. The PE-backed parent's decision to carve it out as a separate sale rather than retain it is worth understanding before engaging on price. The most common explanations for this type of parent carve-out are portfolio concentration (the parent has too much vascular exposure and is diversifying), management bandwidth (the parent cannot operate the clinic effectively alongside its core business), or a strategic mismatch (the clinic's procedure focus does not fit the parent's primary care or multi-specialty model). The 4.64x cash flow ask is reasonable for a growing vascular specialty clinic, but the "niche procedures" description is deliberately vague and the buyer needs to know what those procedures are before any valuation discussion is meaningful. Vascular clinics derive revenue from a wide range of services with very different margin and regulatory profiles: non-invasive vascular testing, arteriovenous fistula creation for dialysis, varicose vein treatment, peripheral arterial disease interventions, and wound care all appear in "vascular" practices and trade differently. Illinois CPOM rules apply to any non-physician ownership structure, and a buyer without an existing physician vehicle will need to structure through an MSO with appropriate medical director arrangements.

Location: Southwest US (undisclosed) | Asking Price: $10.0M | Revenue: $10.0M | EBITDA: $2.5M | EBITDA Margin: 25% | Price / Revenue: 1.0x | Price / EBITDA: 4.0x

Physician-founded, multispecialty chronic-care platform operating as an MSO in the Southwestern US with nearly two decades of operating history. Services include wound management, infectious disease, podiatry, endocrinology, and vascular surgery across multiple outpatient facilities and a fully equipped vascular and vein lab. Preferred provider status with major commercial insurers and Medicare Advantage plans covering over 800,000 lives. Seeking a strategic or capital partner to accelerate expansion.

My take: The preferred provider status with 800,000 covered lives is an interesting asset, and it’s also the asset that requires the most careful diligence. Preferred provider relationships with major commercial payers and Medicare Advantage plans in wound care can be difficult to obtain: they require demonstrated outcomes data, compliance infrastructure, and an existing patient volume that makes the network inclusion meaningful for the payer. If those relationships are durable and contractually documented rather than informal or at-will, the 4.0x ask is very reasonable. If they are relationship-dependent and will be renegotiated on a change of ownership, the business may be worth materially less. The MSO structure is well-suited for a category like wound care, where the clinical operations are physician-performed but the management infrastructure (scheduling, billing, compliance, supply chain for wound care products) can be separated under a management services agreement. Any buyer should conduct a full review of the existing MSO agreements, the physician compensation structure for AKS/Stark compliance, and the payer contract terms before closing. The 25% EBITDA margin is strong for a multi-specialty chronic care platform and is probably driven by the wound care and vascular procedure mix, which carries higher per-visit revenue than primary care or general podiatry.

Location: Florida | Asking Price: $16.0M | Revenue: $6.5M | Cash Flow: $1.8M | CF Margin: 27.7% | Price / Revenue: 2.46x | Price / Cash Flow: 8.88x

Five-location dialysis center network in Florida with established patient base, experienced staff, and scalable operations. State-of-the-art facilities with strong patient retention.

My take: Dialysis is one of the most heavily regulated and payer-concentrated categories in healthcare services: approximately 90% of end-stage renal disease patients are covered by Medicare, and reimbursement rates are set by CMS under the ESRD bundled payment model. The 27.7% cash flow margin reported here is great but it carries regulatory footnotes. DaVita and Fresenius dominate the dialysis market with well over 70% combined market share, and U.S. Renal Care accounts for much of the remainder. As a result, an independent five-location network exists either because it serves markets or demographics the national chains have not prioritized, or because it has physician ownership structures or referral relationships that create competitive insulation. The 8.88x cash flow ask is similar to where the public companies trade, which is unusual in healthcare generally but actually isn’t uncommon in the dialysis market. The primary reason is that the three primary buyers in this market can overlay their beneficial supplier and commercial payer contracts (often 4x+ Medicare believe it or not for the small slice of commercial in the mix). You probably don’t have this benefit. The 2.5x revenue figure would actually be the fourth highest in our database of 45 closed dialysis deals with disclosed financial details. It’s really unclear why these guys called a broker in Canada to list this rather than the three buyers who can pay more than anyone else.

Location: Southern California | Asking Price: $9.0M | Revenue: $10.2M | Price / Revenue: 0.88x

JCAHO-accredited, Medicare-certified hospice agency with over 20 years of operating history and multiple locations in Southern California. Payer mix: 75% Medicare, 10% Medicaid, 15% private insurance. Current census of 138 patients. Staff expected to remain under new ownership.

My take: The 0.88x revenue ask on a 20-plus-year hospice agency with JCAHO accreditation and 138 active patients is at the very low end of the current hospice comp set, and the reason is likely operational rather than strategic: the Gentiva transaction announced this week at 2.29x revenue at scale illustrates the premium that accompanies size and market position. At $10.2 million in revenue with 138 patients, this is a smaller operator in a large market where scale matters for managed care contracting, referral source maintenance, and physician engagement. The Southern California hospice market is competitive, with national players, regional chains, and nonprofit providers all competing for referral relationships. The JCAHO accreditation and 20-year operating history are valuable assets, though. Maybe the 0.88x multiple reflects labor market regulation and the cost and complexity of California's CHOW process for hospice providers, which requires CDPH approval and can take six months or more, as well as the size discount relative to what a platform buyer would pay for a business three to five times this size. For a buyer with existing California hospice operations looking for a geographic tuck-in, the accreditation and patient census make this worth engaging on. For a first-time hospice buyer, the California regulatory environment warrants dedicated advisory resources before closing.

That's it for Issue #10. Forward to one person, reply with feedback, and reach out directly if you are exploring a transaction, valuation, or FMV engagement.

Will Hamilton, CVA

Founder, Scope Research and HealthFMV

The Weekly Checkup is published every Tuesday morning. Written for general informational purposes. Engagements through Scope Research or HealthFMV require a separate agreement.